Literature DB >> 2674856

Direct sequencing analysis of exon 1 of the c-K-ras gene shows a low frequency of mutations in human pancreatic adenocarcinomas.

N F Gonzalez-Cadavid1, D Zhou, H Battifora, M Bar-Eli, M J Cline.   

Abstract

We have applied direct dideoxy sequencing of DNA fragments amplified in vitro by the polymerase chain reaction to the detection of mutations in exon 1 of the c-K-ras gene in human pancreatic adenocarcinomas. Four fresh frozen primary tumors, one metastatic tumor, and twelve formalin-fixed paraffin embedded tumors were analysed. Only three cases showed a possible mutation in codon 12 in a small population of cells, in contrast to the high frequency reported for this alteration with the RNAase A protection assay and allele-specific oligoxynucleotide hybridization. No major difference in sensitivity was found between DNA sequence analysis, and the latter method. Our results suggest that if c-K-ras mutations are indeed present in pancreatic adenocarcinomas at the high frequency reported by others, they must be confined to a small fraction of the cell population to escape detection by direct sequencing. Such a phenomenon would have implications for c-K-ras mutations in the pathogenesis of pancreatic adenocarcinomas.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2674856

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

Review 1.  K-ras mutation and pancreatic adenocarcinoma.

Authors:  C Caldas; S E Kern
Journal:  Int J Pancreatol       Date:  1995-08

Review 2.  The use of molecular technology in the differentiation of pancreatic cancer and chronic pancreatitis.

Authors:  S R Bramhall
Journal:  Int J Pancreatol       Date:  1998-04

3.  Overexpression of c-Ki-ras and c-fos in human pancreatic carcinomas.

Authors:  K Wakita; H Ohyanagi; K Yamamoto; T Tokuhisa; Y Saitoh
Journal:  Int J Pancreatol       Date:  1992-02

4.  A multiplex SNaPshot assay as a rapid method for detecting KRAS and BRAF mutations in advanced colorectal cancers.

Authors:  Sandrine Magnin; Erika Viel; Alice Baraquin; Severine Valmary-Degano; Bernadette Kantelip; Jean-Luc Pretet; Christiane Mougin; Marthe Bigand; Benoît Girardo; Christophe Borg; Christophe Ferrand
Journal:  J Mol Diagn       Date:  2011-07-08       Impact factor: 5.568

5.  Investigational Strategies for Detection and Intervention in Early-Stage Pancreatic Cancer. April 24-27, Annapolis, Maryland. Abstracts.

Authors: 
Journal:  Int J Pancreatol       Date:  1994 Oct-Dec

6.  Molecular differences between human and experimental pancreaticobiliary diversion-induced rat pancreatic neoplasia.

Authors:  P A Hall; N R Lemoine; G Murphy; R H Dowling
Journal:  Gut       Date:  1991-05       Impact factor: 23.059

7.  Prevalence of activating K-ras mutations in the evolutionary stages of neoplasia in intraductal papillary mucinous tumors of the pancreas.

Authors:  K Z'graggen; J A Rivera; C C Compton; M Pins; J Werner; C Fernández-del Castillo; D W Rattner; K B Lewandrowski; A K Rustgi; A L Warshaw
Journal:  Ann Surg       Date:  1997-10       Impact factor: 12.969

Review 8.  K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization.

Authors:  R H Hruban; A D van Mansfeld; G J Offerhaus; D H van Weering; D C Allison; S N Goodman; T W Kensler; K K Bose; J L Cameron; J L Bos
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

9.  Activated KrasG¹²D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin.

Authors:  S Rachagani; S Senapati; S Chakraborty; M P Ponnusamy; S Kumar; L M Smith; M Jain; S K Batra
Journal:  Br J Cancer       Date:  2011-03-01       Impact factor: 7.640

10.  High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer.

Authors:  Michael Krypuy; Genni M Newnham; David M Thomas; Matthew Conron; Alexander Dobrovic
Journal:  BMC Cancer       Date:  2006-12-21       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.